Advertisement

Pharmakokinetische Prinzipien und spezielle Pharmakokinetik der Antiarrhythmika

  • E. Jähnchen
  • D. Trenk
Part of the Handbuch der inneren Medizin book series (INNEREN, volume 9 / 1)

Zusammenfassung

Eine wissenschaftlich fundierte Arzneimitteltherapie setzt die Beachtung genereller pharmakokinetischer Prinzipien voraus. Das gilt insbesondere für die antiarrhythmische Therapie, da einerseits therapeutische und toxische Wirkungen der Antiarrhythmika in einer direkten Beziehung zur Konzentration dieser Pharmaka im Blut oder Plasma stehen, und andererseits nur ein sehr enger Konzentrationsbereich existiert, innerhalb dessen Grenzen eine effektive Therapie möglich ist.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Achilli A, Serra N (1981) Amiodarone increases plasma digoxin concentrations. Br Med J 282:1630Google Scholar
  2. Affrime M, Reidenberg MM (1975) The protein binding of some drugs in plasma from patients with alcoholic liver disease. Eur J Clin Pharmacol 8:167–269Google Scholar
  3. Aito ML (1981) The effect of enzyme induction on the metabolism of disopyramide in man. Br J Clin Pharmacol 11:279–285Google Scholar
  4. Aito ML, Vuorenmaa T (1980) Enhanced metabolism and diminished efficacy of disopyramide by enzyme induction? Br J Clin Pharmacol 9:149–152Google Scholar
  5. Alderman EL, Kerber RE, Harrison DC (1974) Evaluation of lidocaine resistance in man using intermittent large-dose infusion technique. Am J Cardiol 34:342–349PubMedGoogle Scholar
  6. Amery WK, Heykants JJP, Xhonneux R, Towse G, Oettel P, Gough DA, Janssen PAJ (1981) Lorcainide (R 15889), a first review. Acta Cardiol 36:207–234PubMedGoogle Scholar
  7. Andreasen F, Husted S, Jakobsen P, Jensen EB (1980) The binding of aprindine to serum proteins with statistical considerations concerning the analysis of binding data. Acta Pharmacol Toxicol (Kbh) 46:105–112Google Scholar
  8. Andreasen F, Agerbaek H, Bjerregaard P, Gøtzsche H (1981) Pharmacokinetics of amiodarone after intravenous and oral administration. Eur J Clin Pharmacol 19:293–299PubMedGoogle Scholar
  9. Anttila M, Tikkanen R, Nieminen L (1978) Pharmacokinetic studies of the antiarrhythmic drugs ajmaline and N-propylajmaline bitartrate in dogs. Arzneim-Forsch/Drug Res 28:397–399Google Scholar
  10. Bär F, Farré J, Gorgels A, Wellens H (1978) Electrophysiological effects of lorcainide, a new antiarrhythmic drug, in man. Circulation [Suppl 57] II:966 (Abstr)Google Scholar
  11. Baines MW, Davies JE, Kellett DN, Munt PL (1976) Some pharmacological effects of disopyramide and a metabolite. J Int Med Res [Suppl I] 4:5–7Google Scholar
  12. Baudinet G, Henrard L, Quinaux N, el Allaf D, de Lendsheere C, Carlier J, Dresse A (1980) Pharmacokinetics of mexiletine in renal insufficiency. Acta Cardiol (Brux) [Suppl] 25:55–65Google Scholar
  13. Bellet S, Zelman SE, Hirsh SA (1952) The intramuscular use of pronestyl (Procain amide). Am J Med 13:145–157PubMedGoogle Scholar
  14. Bender F, Brisse B, Biechl E (1974) Aprindin, eine neue Substanz zur Behandlung von Extrasystolen. Med Klin 69:1124–1129PubMedGoogle Scholar
  15. Benowitz N (ed) (1974) Clinical applications of the pharmacokinetics of lidocaine. In: Melmon. Cardiovascular drug therapy. Davis, Philadelphia, pp 77–101Google Scholar
  16. Benowitz N, Forsyth RP, Melmon KL, Rowland M (1974) Lidocaine disposition in monkey and man. II. Effects of hemorrhage and sympathomimetic drug administration. Clin Pharmacol Ther 16:99–109PubMedGoogle Scholar
  17. Bernstein V, Bernstein M, Griffiths J, Peretz DI (1972) Lidocaine intramuscularly in acute myocardial infarction. JAMA 219:1027–1031PubMedGoogle Scholar
  18. Bigger JT, Schmidt DH, Kutt H (1968) Relationship between the plasma level of diphenylhydantoin sodium and its cardiac antiarrhythmic effects. Circulation 38:363–374PubMedGoogle Scholar
  19. Blanke H, Aschbrenner B, Karsch KR, Kreuzer H (1979) Plasmaspiegel-Wirkungs-Beziehung und Organverteilung von Propafenon. Dtsch Med Wochenschr 104:587–591PubMedGoogle Scholar
  20. Blaschke TF, Meffin PJ, Melmon KL, Rowland M (1975) Influence of acute viral hepatitis on phenytoin kinetics and protein binding. Clin Pharmacol Ther 17:685–691PubMedGoogle Scholar
  21. Blumer J, Strong JM, Atkinson AJ (1973) The convulsant potency of lidocaine and its N-dealkylated metabolites. J Pharmacol Exp Ther 180:31–36Google Scholar
  22. Bonara MR, Guentert TW, Upton RA, Riegelman S (1979) Determination of quinidine and metabolites in urine by reverse-phase high-pressure liquid chromatography. Clin Chim Acta 91:277–284Google Scholar
  23. Boston Collaborative Drug Surveillance Program (1973) Diphenylhydantoin side effects and serum albumin levels. Clin Pharmacol Ther 14:529–532Google Scholar
  24. Boyes RN, Scott DB, Jebson PJ, Goodman MJ, Julian DG (1971) Pharmacokinetics of lidocaine in man. Clin Pharmacol Ther 12:105–116PubMedGoogle Scholar
  25. Bradbrook ID, Feldschreiber P, Morrison PJ, Rogers HJ, Spector RG (1981) Plasma mexiletine concentrations following combined oral and intramuscular administration. Eur J Clin Pharmacol 19:301–304PubMedGoogle Scholar
  26. Branch RA, Shand DG, Wilkinson GR, Nies AS (1973) The reduction of lidocaine clearance by d,l-propranolol: an example of hemodynamic drug interaction. J Pharmacol Exp Ther 184:515–519PubMedGoogle Scholar
  27. Breithardt G, Seipel L, Abendroth R-R (1981) Comparison of the antiarrhythmic efficacy of disopyramide and mexiletine against stimulus-induced ventricular tachycardia. J Cardiovasc Pharmacol 3:1026–1037PubMedGoogle Scholar
  28. Brennan RW, Dehajia H, Kutt H, Verebely K, McDowell F (1970) Diphenylhydantoin intoxication attendant to slow inactivation of isoniazid. Neurology 20:687–693PubMedGoogle Scholar
  29. Broekhuysen J, Laruel R, Sion R (1969) Recherches dans la série des benzufuranes. XXXVII. Etude comparée du transit et du métabolisme de l’amiodarone chez diverses espèces animales et chez l’homme. Arch Int Pharmacodyn Ther 177:340–359PubMedGoogle Scholar
  30. Brown JE, Shand DG (1982) Therapeutic drug monitoring of antiarrhythmic agents. Clin Pharmacokinet 7:125–148PubMedGoogle Scholar
  31. Bruni J, Gallo JM, Lee CS, Perchalski RJ, Wilder BJ (1980) Interactions of valproic acid with phenytoin. Neurology 30:1233–1236PubMedGoogle Scholar
  32. Bryson SM, Whiting B, Lawrence JR (1978) Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability. Br J Clin Pharmacol 6:409–419PubMedGoogle Scholar
  33. Buckman K, Claiborne K, deGuzman M, Walberg CB, Haywood LJ (1980) Lidocaine efficacy and toxicity assessed by a new, rapid method. Clin Pharmacol Ther 28:177–181PubMedGoogle Scholar
  34. Butler TC (1957) The metabolic conversion of 5,5-diphenylhydantoin to 5-(p-hydroxyphenyl)5-phenyl-hydantoin. J Pharmacol Exp Ther 119:1–11PubMedGoogle Scholar
  35. Campbell NPS, Chaturvedi NC, Kelly JG, Strong JE, Shanks RG, Pantridge JF (1973) Mexiletine (Kö 1173) in the management of ventricular dysrhythmias. Lancet 2:404–407PubMedGoogle Scholar
  36. Campbell NPS, Kelly JG, Adgey AAJ, Shanks RG (1978 a) The clinical pharmacology of mexiletine. Br J Clin Pharmacol 6:103–108PubMedGoogle Scholar
  37. Campbell NPS, Kelly JG, Adgey AAJ, Shanks RG (1978b) Mexiletine in normal volunteers. Br J Clin Pharmacol 6:372–373PubMedGoogle Scholar
  38. Campbell NPS, Pantridge JF, Adgey AAJ (1978 c) Long-term oral antiarrhythmic therapy with mexiletine. Br Heart J 40:796–801PubMedGoogle Scholar
  39. Carliner NH, Fisher ML, Crouthamel WG, Narang PK, Plotnick GD (1980) Relation of ventricular premature beat suppression to serum quinidine concentration determined by a new and specific assay. Am Heart J 100:483–489PubMedGoogle Scholar
  40. Cocco G, Strozzi C (1978) Initial clinical experience of lorcainide, a new antiarrhythmic agent. Eur J Clin Pharmacol 14:105–109PubMedGoogle Scholar
  41. Collinsworth KA, Strong JM, Atkinson AJ, Winkle RA, Perlroth F, Harrison DC (1975) Pharmacokinetics and metabolism of lidocaine in patients with renal failure. Clin Pharmacol Ther 18:59–64PubMedGoogle Scholar
  42. Covinsky JO, Russo J, Kelly KL, Cashman J, Amick EN, Mason WD (1979) Relative bioavailability of quinidine gluconate and quinidine sulfate in healthy volunteers. J Clin Pharmacol 19:261–269PubMedGoogle Scholar
  43. Cunningham JL, Shen DD, Shudo I, Azarnoff DL (1977) The effects of urine pH and plasma protein binding on the renal clearance of disopyramide. Clin Pharmacokin 2:373–383Google Scholar
  44. Cunningham JL, Shen DD, Shudo I, Azarnoff DL (1978) The effect of non-linear disposition kinetics on the systemic availability of disopyramide. Br J Clin Pharmacol 5:343–346Google Scholar
  45. Dahlqvist R, Ejvinsson G, Schenk-Gustafsson K (1980) Effect of quinidine on plasma concentration and renal clearance of digoxin. A clinically important drug interaction. Br J Clin Pharmacol 9:413–418PubMedGoogle Scholar
  46. Danilo P, Rosen MR (1976) Cardiac effects of disopyramide. Am Heart J 92:532–536PubMedGoogle Scholar
  47. Data JL, Wilkinson JR, Nies AS (1976) Interaction of quinidine with anticonvulsant drugs. N Engl J Med 294:699–702PubMedGoogle Scholar
  48. Delcroix C, Martin L, van Durme JP, Kesteloot H, Hagemeijer F, Mbuyamba P, Deblecker M (1974) Model for exchange kinetics of aprindine in man after single and multiple doses. Acta Cardiol (Brux) [Suppl] 18:177–194Google Scholar
  49. Dengler HJ, Eichelbaum M (1977) Polymorphismen und Defekte des Arzneimittelstoffwechsels als Ursache toxischer Reaktionen. Arzneim-Forsch/Drug Res 27:1836–1844Google Scholar
  50. Dengler HJ, Eichelbaum M, Hengstmann J, Wieber J (1970) Pharmacokinetic studies in man with sparteine. Pharmacol Clin 2:189–195Google Scholar
  51. Difazio CA, Brown RF (1972) Lidocaine metabolism in normal and phenobarbital pretreated dogs. Anaesthesiology 36:238–243Google Scholar
  52. Dodion L, De Suray JM, Deblecker M, Georges A (1974) Caractéristiques pharmacocinétiques et biodégradation de l’aprindine chez l’homme. Thérapie 29:221–232PubMedGoogle Scholar
  53. Doering W (1979) Quinidine — digoxin interaction: Pharmacokinetics, underlaying mechanisms, and clinical implications. N Engl J Med 301:400–404PubMedGoogle Scholar
  54. Dominic J, McAllister RG, Kuo C-S, Reddy CP, Surawicz B (1979) Verapamil plasma levels and ventricular rate response in patients with atrial fibrillation and flutter. Clin Pharmacol Ther 26:710–714PubMedGoogle Scholar
  55. Drayer DE, Reidenberg MM, Sevy RW (1974) N-acetylprocainamide: An active metabolite of procainamide. Proc Soc Exp Biol Med 146:358–363PubMedGoogle Scholar
  56. Drayer DE, Restivo KM, Reidenberg MM (1977) Specific determination of quinidine and (3S)-3-hydroxyquinidine in human serum by high pressure liquid chromatography. J Lab Clin Med 90:816–822PubMedGoogle Scholar
  57. Drayer DE, Löwenthal DT, Restivo KM, Schwartz A, Cooke CE, Reidenberg MM (1978) Steady-state serum levels of quinidine and active metabolites in cardiac patients with various degrees of renal function. Clin Pharmacol Ther 24:31–39PubMedGoogle Scholar
  58. Drayer DE, Hughes M, Lorenzo B, Reidenberg MM (1980) Prevalence of high (3S)-3-hydroxyquinidine/quinidine ratios in serum, and clearance of quinidine in cardiac patients with age. Clin Pharmacol Ther 27:72–75PubMedGoogle Scholar
  59. Dreifus LS, Lim HF, Watanabe Y, McKnight E, Frank MN (1968) Propranolol and quinidine in the management of ventricular tachycardia. JAMA 204:190–191Google Scholar
  60. Dubetz DK, Braun NN, Hooper WD, Eadie MJ, Tyrer JH (1978) Disopyramide pharmacokinetics and bioavailability. Br J Clin Pharmacol 6:279–281PubMedGoogle Scholar
  61. Du Souich P, Erill S (1977) Metabolism of procainamide and p-aminobenzoic acid in patients with chronic liver disease. Clin Pharmacol Ther 22:588–595PubMedGoogle Scholar
  62. Eichelbaum M, Spannbrucker N, Dengler HJ (1979 a) Influence of the defective metabolism of sparteine on its pharmacokinetics. Eur J Clin Pharmacol 16:189–194PubMedGoogle Scholar
  63. Eichelbaum M, Ende M, Remberg G, Schomerus M, Dengler HJ (1979b) The metabolism of D,L-(14C)-verapamil in man. Drug Metab Dispos 7:145–148PubMedGoogle Scholar
  64. Eichelbaum M, Birkel P, Grube E, Gütgemann U, Somogyi A (1980a) Effects of verapamil on P-R-intervals in relation to verapamil plasma levels following single iv and oral administration and during chronic treatment. Klin Wochenschr 58:919–925PubMedGoogle Scholar
  65. Eichelbaum M, Albrecht M, Kliems G, Schäfer K, Somogyi A (1980b) Influence of meso-caval shunt surgery on verapamil kinetics, bioavailability and response. Br J Clin Pharmacol 10:527–529PubMedGoogle Scholar
  66. Eichelbaum M, Somogyi A, von Unruh GE, Dengler HJ (1981) Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labeled verapamil. Eur J Clin Pharmacol 19:133–137PubMedGoogle Scholar
  67. Ejvinsson G (1978) Effect of quinidine on plasma concentrations of digoxin. Br Med J 1:279–280PubMedGoogle Scholar
  68. Elson J, Strong JM, Lee WK, Atkinson AJ (1975) Antiarrhythmic potency of N-acetylprocainamide. Clin Pharmacol Ther 17:134–140PubMedGoogle Scholar
  69. Elvin AT, Keenaghan JB, Byrnes EW, Tenthorey PA, McMaster PD, Takman BH, Lalka D, Manion CV, Baer TD, Wolshin EM, Meyer MB, Ronfeld RA (1980) Tocainide conjugation in humans: Novel biotransformation pathway for a primary amine. J Pharm Sci 69:47–49PubMedGoogle Scholar
  70. Enselberg CD, Lipkin M (1952) The intramuscular administration of procainamide: A safe and effective method for the treatment of cardiac arrhythmias. Am Heart J 44:781–786PubMedGoogle Scholar
  71. Eriksson J-E, Hanson A, Hörlin R, Johansson BW, Ohlsson O, Otto U, Syren G (1979) Evaluation of quinidine lipettes — a sustained release preparation. Acta Med Scand 205:53–59PubMedGoogle Scholar
  72. Fasola AF, Carmichael R (1974) The pharmcology and clinical evaluation of aprindine a new antiarrhythmic agent. Acta Cardiol (Brux) [Suppl] 18:317–333Google Scholar
  73. Fehmers MCO, Dunning AJ (1972) Intramusculary and orally administered lidocaine in the treatment of ventricular arrhythmias in acute myocardial infarction. Am J Cardiol 29:514–519PubMedGoogle Scholar
  74. Fincham RW, Schottelius DD (1979) Decreased phenytoin levels in antineoplastic therapy. Ther Drug Monitor 1:277–283Google Scholar
  75. Fincham RW, Wiley DE, Schottelius DD (1976) Use of phenytoin serum levels in a case of status epilepticus. Neurology 26:879–881PubMedGoogle Scholar
  76. Flanagan RJ, Storey GCA, Holt DW (1980) Rapid high-performance liquid chromatographic method for the measurement of amiodarone in blood plasma or serum at the concentrations attained during therapy. J Chromatogr 187:391–398PubMedGoogle Scholar
  77. Foldes FF, Molloy R, McNall PG, Koukal LR (1960) Comparison of toxicity of intravenously given local anaesthetic agents in man. JAMA 172:1493–1498Google Scholar
  78. Forssell G, Graffner C, Nordlander R, Nyquist O (1980) Comparative bioavailability of disopyramide after multiple dosing with standard capsules and controlled-release tablets. Eur J Clin Pharmacol 17:209–213PubMedGoogle Scholar
  79. Freyland MD, Steffel D, Hilger HH (1975) Klinische Erfahrungen mit dem neuen Antiarrhythmicum Aprindin anhand von Langzeit-Trendanalysen. Dtsch Med Wochenschr 100:1764–1767PubMedGoogle Scholar
  80. Frigo GM, Perucca E, Teggia-Drighi M, Gatti G, Mussini A, Salerno J (1977) Comparison of quinidine plasma concentration curves following oral administration of some short- and long-acting formulations. Br J Clin Pharmacol 4:449–454PubMedGoogle Scholar
  81. Galeazzi RL, Benet LZ, Sheiner LB (1976) Relationship between the pharmacokinetics and pharmacodynamics of procainamide. Clin Pharmacol Ther 20:278–289PubMedGoogle Scholar
  82. Garratt WR, Carter BL, Pellock JM (1979) Bioavailability of phenytoin administered with antacids. Ther Drug Monitor 1:435–437Google Scholar
  83. Gerber N, Wagner JG (1972) Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation. Res Commun Chem Pathol Pharmacol 3:455–466PubMedGoogle Scholar
  84. Giacomini K, Giacomini J, Blaschke T (1980) Heparin decreases plasma protein binding of drugs. Clin Pharmacol Ther 27:256Google Scholar
  85. Gianelly R, von der Groeben JO, Spivack AP, Harrison DC (1967) Effect of lidocaine on ventricular arrhythmias in patients with coronary heart disease. N Engl J Med 277:1215–1219PubMedGoogle Scholar
  86. Giardina EGV, Heissenbüttel RH, Bigger JT (1973) Intermittent intravenous procainamide to treat ventricular arrhythmias: Correlation of plasma concentration with effect on arrhythmia, electrocardiogram, and blood pressure. Ann Intern Med 78:183–193PubMedGoogle Scholar
  87. Gibson TP, Atkinson AJ, Matusik E, Nelson LD, Briggs WA (1977) Kinetics of procainamide and N-acetylprocainamide in renal failure. Kidney Int 12:422–429PubMedGoogle Scholar
  88. Gibson TP, Matusik J, Matusik E, Nelson HA, Wilkinson J, Briggs WA (1975) Acetylation of procainamide in man and its relationship to isonicotinic acid hydrazine acetylation phenotype. Clin Pharmacol Ther 17:395–399PubMedGoogle Scholar
  89. Glazko AJ, Chang T, Baukema J, Dill WA, Goulet JR, Buchanan RA (1969) Metabolic disposition of diphenylhydantoin in normal human subjects following intravenous administration. Clin Pharmacol Ther 10:498–504PubMedGoogle Scholar
  90. Graffner C, Johnsson G, Sjögren J (1975) Pharmacokinetics of procainamide intravenously and orally as conventional and slow-release tablets. Clin Pharmacol Ther 17:414–423PubMedGoogle Scholar
  91. Graffner C, Jansson R-M, Lagerstrom P-O, Persson B-A (1977) Disposition of procainamide and its N-acetylated metabolite after acute IV infusion in man determined by high speed liquid chromatography. Eur J Drug Metab Pharmacokin 1:29–36Google Scholar
  92. Graffner C, Conradson T-B, Hofvendahl S, Rydén L (1980) Tocainide kinetics after intravenous and oral administration in healthy subjects and in patients with acute myocardial infarction. Clin Pharmacol Ther 27:64–71PubMedGoogle Scholar
  93. Grant AM, Marshall RJ, Ankier SI (1978) Some effects of disopyramide and its N-dealkylated metabolite on isolated nerve and cardiac muscle. Eur J Pharmacol 49:389–394PubMedGoogle Scholar
  94. Greenblatt DJ, Bolognini V, Koch-Weser J, Harmatz JS (1976) Pharmacokinetic approach to the clinical use of lidocaine intravenously. JAMA 236:273–277PubMedGoogle Scholar
  95. Greenblatt DJ, Pfeifer HJ, Ochs HR, Franke K, MacLaughlin DS, Smith DW, Koch-Weser J (1977) Pharmacokinetics of quinidine in humans after intravenous, intramuscular and oral administration. J Pharmacol Exp Ther 202:365–378PubMedGoogle Scholar
  96. Grundevik I, Persson BA (1982) Assay of n-propylajmaline in blood plasma by ion-pair liquid-liquid chromatography. J Liq Chromatogr 5:141–150Google Scholar
  97. Guentert TW, Coates PE, Upton RA, Combs DL, Riegelman S (1979) Determination of quinidine and its major metabolites by high-performance liquid chromatography. J Chromatogr 162:59–70PubMedGoogle Scholar
  98. Gugler R, Shoeman DW, Huffman DH, Cohlmia JB, Azarnoff DL (1975) Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest 55:1182–1189PubMedGoogle Scholar
  99. Gugler R, Manion CV, Azarnoff DL (1976) Phenytoin: Pharmacokinetics and bioavailability. Clin Pharmacol Ther 19:135–142PubMedGoogle Scholar
  100. Haasis R, Mikulla A, Roth W (1980) Klinische Studie zur Interaktion zwischen Prajmaliumbitartrat und β-Methyldigoxin. Med Welt 43:1560–1562Google Scholar
  101. Häselbarth V, Doevendans JE, Wolf M (1981) Kinetics and bioavailability of mexiletine in healthy subjects. Clin Pharmacol Ther 29:729–736PubMedGoogle Scholar
  102. Hagemeijer F (1975) Absorption, half-life, and toxicity of oral aprindine in patients with acute myocardial infarction. Eur J Clin Pharmacol 9:21–25PubMedGoogle Scholar
  103. Hager WD, Fenster P, Mayerson M, Perrier D, Graves P, Marcus FI, Goldman S (1979) Digoxin — quinidine interaction: Pharmacokinetic evaluation. N Engl J Med 300:1238–1241PubMedGoogle Scholar
  104. Halkin H, Meffin P, Melmon KL, Rowland M (1975) Influence of congestive heart failure on blood levels of lidocaine and its active monodeethylated metabolite. Clin Pharmacol Ther 17:669–676PubMedGoogle Scholar
  105. Hansen JM, Kampmann JP, Siersbaek-Nielsen K, Lumholtz IB, Arrøe M, Abildgaard V, Skovsted L (1979) The effect of different sulfonamides on phenytoin metabolism in man. Acta Med Scand [Suppl] 624:106–110Google Scholar
  106. Harrison DC, Meffin PJ, Winkle RA (1977) Clinical pharmacokinetics of antiarrhythmic drugs. Prog Cardiovasc Dis 20:217–242PubMedGoogle Scholar
  107. Heissenbuttel RH, Bigger JT (1970) The effect of oral quinidine on intraventricular conduction in man: Correlation of plasma quinidine with changes in QRS duration. Am Heart J 80:453–462PubMedGoogle Scholar
  108. Hempel E, Klinger W (1976) Drug stimulated biotransformation of hormonal steroid contraceptives: Clinical implications. Drugs 12:442–448PubMedGoogle Scholar
  109. Herzog P, Holtermüller KH, Kasper W, Meinertz T, Trenk D, Jähnchen E (1982) Absorption of mexiletine after treatment with gastric antacids. Br J Clin Pharmacol 14:746–747PubMedGoogle Scholar
  110. Hetzel DJ, Bochner F, Hallpike JF, Shearman DJC, Hann CS (1981) Cimetidine interaction with phenytoin. Br Med J 282:1512Google Scholar
  111. Heykants J (1981) Comparative pharmacokinetics of lorcainide in rats, dogs and man. In: Jähnchen E, Meinertz T, Towse G (eds) Prognosis and pharmacotherapy of life-threatening arrhythmias. Royal Society of Medicine. Int Congress and Symposium Series No 49. Academic Press, London, pp 35–39Google Scholar
  112. Hinderling PH, Garrett ER (1976 a) Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans. J Pharmacokin Biopharm 4:199–230Google Scholar
  113. Hinderling PH, Garrett ER (1976 b) Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans: Correlation of the kinetics of the drug and its effects. J Pharmacokin Biopharm 4:231–242Google Scholar
  114. Holford NHG, Coates PE, Guentert TW, Riegelman S, Sheiner LB (1981) The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: Concentration — effect relationships. Br J Clin Pharmacol 11:187–195PubMedGoogle Scholar
  115. Hollmann B (1982) Pharmacokinetics of propafenone. In: Schlepper M (Hrsg) 1. Internationaler Rytmonorm-Kongreß, München. Springer, Berlin Heidelberg New YorkGoogle Scholar
  116. Hooper WD, Bochner F, Eadie MJ, Tyrer JH (1974) Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease. Clin Pharmacol Ther 15:276–282PubMedGoogle Scholar
  117. Hooymans P, Holford N, Massie B, Witt M, Pluym B, Merkus F (1980) Quinidine decreases both renal and metabolic clearance of digoxin. Am J Cardiol 45:453Google Scholar
  118. Hughes IE, Ilett KF, Jeilert LB (1975) The distribution of quinidine in human blood. Br J Clin Pharmacol 2:521–525PubMedGoogle Scholar
  119. Ilett KF, Madson BW, Woods JD (1979) Pharmacokinetics of disopyramide in patients with acute myocardial infarction. Clin Pharmacol Ther 26:1–7PubMedGoogle Scholar
  120. Jähnchen E, Bechtold H, Kasper W, Kersting F, Just H, Heykants J, Meinertz T (1979) Lorcainide I. Saturable presystemic elimination. Clin Pharmacol Ther 26:187–195PubMedGoogle Scholar
  121. Johnston A, Burgess CD, Warrington SJ, Wadsworth J, Hamer NAJ (1979) The effect of spontaneous changes in urinary pH on mexiletine plasma concentrations and excretion during chronic administration to healthy volunteers. Br J Clin Pharmacol 8:349–352PubMedGoogle Scholar
  122. Johnston A, Henry JA, Warrington SJ, Hamer NAJ (1980) Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment. Br J Clin Pharmacol 10:245–248PubMedGoogle Scholar
  123. Jusko WJ, Koup JR, Alvan G (1976) Nonlinear assessment of phenytoin bioavailability. J Pharmacokin Biopharm 4:327–336Google Scholar
  124. Karlsson E, Molin L (1975) Polymorphic acetylation of procainamide in healthy subjects. Acta Med Scand 197:299–302PubMedGoogle Scholar
  125. Kates RE, Blanford MF (1979) Disposition kinetics of oral quinidine when administered concurrently with propranolol. J Clin Pharmacol 19:378–383PubMedGoogle Scholar
  126. Kates RE, Keefe DLD, Schwartz J, Harapat S, Kirsten EB, Harrison DC (1981) Verapamil disposition kinetics in chronic atrial fibrillation. Clin Pharmacol Ther 30:44–51PubMedGoogle Scholar
  127. Keefe DLD, Yee Y-G, Kates RE (1981) Verapamil protein binding in patients and in normal subjects. Clin Pharmacol Ther 29:21–26PubMedGoogle Scholar
  128. Keller K, Meyer-Estorf G, Beck OA, Hochrein H (1978) Correlation between serum concentration and pharmacological effect on atrioventricular conduction time of the antiarrhythmic drug propafenone. Eur J Clin Pharmacol 13:17–20PubMedGoogle Scholar
  129. Kessler KM, Löwenthal DT, Warner H, Gibson T, Briggs W, Reidenberg MM (1974) Quinidine elimination in patients with congestive heart failure or poor renal function. N Engl J Med 290:706–709PubMedGoogle Scholar
  130. Kessler KM, Humphries WC, Black M, Spann JF (1978) Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol. Am Heart J 96:627–635PubMedGoogle Scholar
  131. Kessler KM, Leech RC, Spann JF (1979) Blood collection techniques, heparin and quinidine protein binding. Clin Pharmacol Ther 25:204–210PubMedGoogle Scholar
  132. Kesteloot H (1974) General aspects of anti-arrhythmic treatment with aprindine. Acta Cardiol (Brux) [Suppl] 18:303–316Google Scholar
  133. Kesteloot H, Stroobandt R (1977) Clinical experience with lorcainide (R 15889), a new anti-arrhythmic drug. Arch Int Pharmacodyn Ther 230:225–234PubMedGoogle Scholar
  134. Kesteloot H, van Mieghem W, de Geest H (1973) Aprindine (AC 1802), a new antiarrhythmic drug. Acta Cardiol (Brux) 28:145–165Google Scholar
  135. Kiddie MA, Kaye CM, Turner P, Shaw TRD (1974) The influence of urinary pH on the elimination of mexiletine. Br J Clin Pharmacol 1:229–232Google Scholar
  136. Klein G, Wirtzfeld A (1980) Pharmakokinetik der gebräuchlichen Antiarrhythmika Chinidin — Lidocain — Propafenon — Disopyramid — Mexiletin — Ajmalin — N-Propyl-Ajmalin — Aprindine — Verapamil. Pharmakotherapie 3:272–288Google Scholar
  137. Kleinsorge H, Gaida P (1961) Ausscheidungsmengen und -geschwindigkeiten des Rauwolfia-Alkaloids Ajmalin nach verschiedenen Applikationsformen. Arzneim-Forsch/Drug Res 11:1100–1102Google Scholar
  138. Kleinsorge H, Gaida P (1962) Das Verhalten des Serumspiegels nach intravenöser Injektion von Ajmalin. Klin Wochenschr 3:149–151Google Scholar
  139. Klotz U, Müller-Seydlitz P, Heimburg P (1978) Pharmacokinetics of lorcainide in man: A new antiarrhythmic agent. Clin Pharmacokin 3:407–418Google Scholar
  140. Klotz U, Müller-Seydlitz P, Heimburg P (1979 a) Disposition and antiarrhythmic effect of lorcainide. Int J Clin Pharmacol Ther 26:152–158Google Scholar
  141. Klotz U, Müller-Seydlitz P, Heimburg P (1979 b) Lorcainide infusion in the treatment of ventricular premature beats (VPB). Eur J Clin Pharmacol 16:1–6PubMedGoogle Scholar
  142. Klotz U, Fischer C, Müller-Seydlitz P, Schultz J, Müller WA (1979c) Alterations in the disposition of differently cleared drugs in patients with cirrhosis. Clin Pharmacol Ther 26:221–227PubMedGoogle Scholar
  143. Koch-Weser J (1971) Pharmacokinetics of procainamide in man. Ann NY Acad Sci 179:370–382PubMedGoogle Scholar
  144. Koch-Weser J, Klein SW (1971) Procainamide dosage schedules, plasma concentrations and clinical effects. JAMA 215:1454–1460PubMedGoogle Scholar
  145. Koike Y, Shimamura N, Shudo I, Saito H (1979) Pharmacokinetics of verapamil in man. Res Commun Chem Pathol Pharmacol 24:37–47PubMedGoogle Scholar
  146. Kuck KH, Hanrath P, Lubda J, Mathey D, Bleifeld W (1979) Die antiarrhythmische Wirkung von Tocainid bei ventrikulären Herzrhythmusstörungen. Dtsch Med Wochenschr 104:1701–1705PubMedGoogle Scholar
  147. Kurata D, Wilkinson GR (1974) Erythrocyte uptake and plasma binding of diphenylhydantoin. Clin Pharmacol Ther 16:355–362PubMedGoogle Scholar
  148. Kutt H (1971) Biochemical and genetic factors regulating Dilantin metabolism in man. Ann NY Acad Sci 179:704–722Google Scholar
  149. Kutt H (1972) Diphenylhydantoin. Interactions with other drugs in man. In: Woodbury et al. (eds) Antiepileptic drugs. Raven Press, New York, pp 169–180Google Scholar
  150. Kutt H, Wolk M, Scherman R, McDowell F (1964a) Insufficient parahydroxylation as a cause of diphenylhydantoin toxicity. Neurology 14:542–548PubMedGoogle Scholar
  151. Kutt H, Winters W, Kokenge R, McDowell F (1964b) Diphenylhydantoin metabolism. blood levels and toxicity. Arch Neurol 11:642–648PubMedGoogle Scholar
  152. Kutt H, Haynes J, McDowell F (1966 a) Some causes of ineffectiveness of diphenylhydantoin. Arch Neurol 14:489–492PubMedGoogle Scholar
  153. Kutt H, Winters W, McDowell FH (1966 b) Depression of parahydroxylation of diphenylhydantoin by antituberculosis chemotherapy. Neurology 16:594–602PubMedGoogle Scholar
  154. Kutt H, Brennan R, Dehajia H, Verebely K (1970) Diphenylhydantoin intoxication. Complication of isoniazid therapy. Am Rev Respir Dis 101:377–384PubMedGoogle Scholar
  155. Lalka D, Meyer MB, Duce BR, Elvin AT (1976) Kinetics of the oral antiarrhythmic lidocaine congener, tocainide. Clin Pharmacol Ther 19:757–766PubMedGoogle Scholar
  156. Landmark K, Bredesen JE, Thanlow E, Simonsen S, Amlie PJ (1981) Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure. Eur J Clin Pharmacol 19:187–192PubMedGoogle Scholar
  157. Leahey EB, Giardina EGV, Reiffei JA, Bigger JT (1978 a) Serum digoxin concentrations during quinidine and procainamide administration. Circulation [Suppl II] 58:101Google Scholar
  158. Leahey EB, Reiffei JA, Drusin RE, Heissenbüttel RH, Lovejoy WP, Bigger JT (1978 b) Interaction between quinidine and digoxin. JAMA 240:533–534PubMedGoogle Scholar
  159. Leahey EB, Heissenbüttel RH, Giardina EGV, Bigger JT (1980) Combined mexiletine and propranolol treatment of refractory ventricular tachycardia. Br Med J 2:358–359Google Scholar
  160. Lee WK, Strong JM, Kehoe RF, Dutcher JS, Atkinson AJ (1976) Antiarrhythmic efficacy of N-acetylprocainamide in patients with premature ventricular contractions. Clin Pharmacol Ther 19:508–514PubMedGoogle Scholar
  161. LeLorier J, Grenon D, Latour Y, Caille G, Dumont G, Brosseau A, Solignac A (1977) Pharmacokinetics of lidocaine after prolonged intravenous infusions in uncomplicated myocardial infarction. Ann Intern Med 87:700–702PubMedGoogle Scholar
  162. Lie KI, Liem KL, Durrer D (1977) Double-blind randomised study of intramuscular lidocaine in preventing primary ventricular fibrillation. Am J Cardiol 39:275Google Scholar
  163. Lie KI, Liem KL, Louridtz WJ, Janse MJ, Durrer D, Willebrands AF (1978) Efficacy of lidocaine in preventing primary ventricular fibrillation within one hour after a 300 mg intramuscular injection. A double-blind randomized study of 300 hospitalized patients with acute myocardial infarction. Am J Cardiol 42:486–488PubMedGoogle Scholar
  164. Ludden TM, Allen JP, Valutsky WA, Vicuna AV, Nappi JM, Hoffman SF, Wallace JE, Lalka D, McNay JL (1977) Individualization of phenytoin dosage regimens. Clin Pharmacol Ther 21:287–293PubMedGoogle Scholar
  165. Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM (1975) Sulfamethiazole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism. Clin Pharmacol Ther 17:731–734PubMedGoogle Scholar
  166. Lunde PKM, Rane A, Yaffe SJ, Lund L, Sjöqvist F (1970) Plasma protein binding of diphenylhydantoin in man. Clin Pharmacol Ther 11:846–855PubMedGoogle Scholar
  167. Manion CV, Lalka D, Baer TD, Meyer MB (1977) Absorption kinetics of procainamide in humans. J Pharm Sci 66:981–984PubMedGoogle Scholar
  168. Marcus FI, Fontaine GH, Frank R, Grosgogeat Y (1981) Clinical pharmacology and therapeutic applications of the antiarrhythmic agent, amiodarone. Am Heart J 101:480–493PubMedGoogle Scholar
  169. Mark LC, Kayden HJ, Steele JM, Cooper JA, Berlin I, Rowenstine EA, Brodie BB (1951) The physiological disposition and cardiac effects of procainamide. J Pharmacol Exp Ther 102:5–15PubMedGoogle Scholar
  170. Mather LD, Thomas J (1972) Metabolism of lidocaine in man. Life Sci 11:915–919Google Scholar
  171. Mattson RH, Cramer JH, Williamson PC, Novelly RA (1978) Valproic acid in epilepsy: Clinical and pharmacological effects. Ann Neurol 3:20–25PubMedGoogle Scholar
  172. McIlhenny HM (1971) Metabolism of (14C)-verapamil. J Med Chem 14:1178–1184PubMedGoogle Scholar
  173. Meffin PJ, Winkle RA, Blaschke TF, Fitzgerald J, Harrison DC, Harapat SR, Bell PA (1977) Response optimization of drug dosage: Antiarrhythmic studies with tocainide. Clin Pharmacol Ther 22:42–57PubMedGoogle Scholar
  174. Meffin PJ, Robert EW, Winkle RA, Harapat S, Peters FA, Harrison DC (1979) Role of concentration-dependent plasma protein binding in disopyramide disposition. J Pharmacokin Biopharm 7:29–46Google Scholar
  175. Meinertz T, Kasper W, Kersting F, Just H, Bechtold H, Jähnchen E (1979) Lorcainide II. Plasma concentration — effect relationship. Clin Pharmacol Ther 26:196–204PubMedGoogle Scholar
  176. Meinertz T, Kasper W, Stengel E, Waldecker B, Löllgen H, Jähnchen E, Bechtold H, Just H (1982) Comparison of the antiarrhythmic activity of mexiletine and lorcainide on ventricular arrhythmias. Z Kardiol 71:35–38PubMedGoogle Scholar
  177. Meyer W, Kaye CM, Turner P (1974) A study of the influence of pH on the buccal absorption and the renal excretion of procainamide. Eur J Clin Pharmacol 7:287–289PubMedGoogle Scholar
  178. Meyer-Estorf G, Keller K, Beck OA, Hochrein H (1978) Antiarrhythmische Wirksamkeit von Propafenon in Abhängigkeit von Serumkonzentration und Erregungsleitungshemmung. Z Kardiol 67:353–356PubMedGoogle Scholar
  179. Moysey JO, Jaggarao NSV, Grundy EN, Chamberlain DA (1981) Amiodarone increases plasma digoxin concentrations. Br Med J 282:272Google Scholar
  180. Murphy PJ (1974) Metabolic pathways of aprindine. Acta Cardiol (Brux) [Suppl] 18:131–142Google Scholar
  181. Myerburg RJ, Kessler KM, Kiem I, Pefkaros K, Conde C, Cooper D, Castellanos A (1981) Relationship between plasma levels of procainamide, suppression of premature ventricular complexes and prevention of recurrent ventricular tachycardia. Circulation 64:280–290PubMedGoogle Scholar
  182. Nappi J (1979) Warfarin and phenytoin interaction. Ann Intern Med 90:852PubMedGoogle Scholar
  183. Neugebauer G (1978) Comparative cardiovascular actions of verapamil and its major metabolites in the anaesthetised dog. Cardiovasc Res 12:247–254PubMedGoogle Scholar
  184. Neuvonen PJ, Lehtovaara R, Bardy A, Elonen E (1979) Antipyrine analgesics in patients on antiepileptic drug therapy. Eur J Clin Pharmacol 15:263–268PubMedGoogle Scholar
  185. Niarchos AP (1976) Disopyramide-serum level and arrhythmia conversion. Am Heart J 92:57–64Google Scholar
  186. Nilson OG, Leren P, Aakesson I, Jacobsen S (1978) Binding of quinidine in sera with different levels of triglycerides, cholesterol, and orosomucoid protein. Biochem Pharmacol 27:871–876Google Scholar
  187. Nimmo J (1977) The development of mexiletine in the treatment of cardiac arrhythmias. Postgrad Med J [Suppl 1] 53:120–123Google Scholar
  188. Nitsch J, Lüderitz B (1982) Interaktion von Mexiletin und Cimetidin — verzögerte Elimination eines Antiarrhythmikums. Verh Dtsch Ges Inn Med 88, Bergmann, MünchenGoogle Scholar
  189. Ochs HR, Greenblatt DJ, Woo E, Smith TW (1978 a) Reduced quinidine clearance in elderly persons. Am J Cardiol 42:481–485PubMedGoogle Scholar
  190. Ochs HR, Greenblatt DJ, Woo E, Franke K, Smith TW (1978 b) Effect of propranolol on pharmacokinetics and acute electrocardiographic changes following intravenous quinidine in humans. Pharmacology 17:301–306PubMedGoogle Scholar
  191. Ochs HR, Greenblatt DJ, Woo E (1980 a) Clinical pharmacokinetics of quinidine. Clin Pharmacokin 5:150–168Google Scholar
  192. Ochs HR, Grulse E, Greenblatt DJ, Woo E, Bodem G (1980b) Intravenous quinidine: Pharmacokinetic properties and effects on left ventricular performance in humans. Am Heart J 99:468–475PubMedGoogle Scholar
  193. Ochs HR, Carstens G, Greenblatt DJ (1980c) Reduction in lidocaine clearance during continous infusion and by coadministration of propranolol. N Engl J Med 303:373–377PubMedGoogle Scholar
  194. Paalman ACA, Roos JC, Siebelink J, Dunning AJ (1977) Development of a dosage scheme for simultaneous intravenous and oral administration of mexiletine. Postgrad Med J [Suppl 1] 53:128–133Google Scholar
  195. Palmer KH, Martin B, Baggett B, Wall ME (1969) The metabolic fate of orally administered quinidine gluconate in humans. Biochem Pharmacol 18:1845–1860Google Scholar
  196. Pedersen KE, Dorph-Pedersen A, Hvidt S, Klitgaard NA, Nielsen-Kudsk F (1981) Digoxin — verapamil interaction. Clin Pharmacol Ther 30:311–316PubMedGoogle Scholar
  197. Perez-Mateo M, Erill S (1977) Protein binding of salicylate and quinidine in plasma from patients with renal failure, chronic liver disease and respiratory insufficiency. Eur J Clin Pharmacol 11:225–231PubMedGoogle Scholar
  198. Perucca E (1982) Pharmacokinetic interactions with antiepileptic drugs. Clin Pharmacokin 7:57–84Google Scholar
  199. Perucca E, Richens A (1980) Anticonvulsant drug interactions. In: Tyrer (ed) The treatment of epilepsy. MTP Press, Lancaster, pp 95–128Google Scholar
  200. Perucca E, Hebdige S, Gatti G, Lecchini S, Frigo GM, Crama A (1980) Interaction between phenytoin and valproic acid: Plasma protein binding and metabolic effects. Clin Pharmacol Ther 28:779–789PubMedGoogle Scholar
  201. Piafsky KM, Knoppert D (1978) Binding of local anaesthetics to α 1 acid glycoprotein. Clin Res 26:836 AGoogle Scholar
  202. Plänitz V, Grönniger J, Jähnchen E (1980) First-pass metabolism of lorcainide in rats with portacaval shunt and following pretreatment with phenobarbital. Naunyn Schmiedebergs Arch Pharmacol [Suppl] 311:R 3Google Scholar
  203. Pottage A, Campbell RWF, Achuff SC, Murray A, Julian DG, Prescott LF (1978) The absorption of oral mexiletine in coronary care patients. Eur J Clin Pharmacol 13:393–400Google Scholar
  204. Prescott LF (1978) Pharmacokinetic abnormalities in myocardial infarction. In: Sandøe E, Julian DG, Bell JW (eds) Management of ventricular tachycardia — role of mexiletine. Excerpta Medica, Amsterdam Oxford, pp 465–471Google Scholar
  205. Prescott LF, Adjepon-Yamoah KK, Talbot RG (1976) Impaired lignocaine metabolism in patients with myocardial infarction and cardiac failure. Br Med J 1:939–941PubMedGoogle Scholar
  206. Prescott LF, Pottage A, Clements JA (1977) Absorption, distribution and elimination of mexiletine. Postgrad Med J [Suppl 1] 53:50–55Google Scholar
  207. Rangno RE, Warnica W, Ogilvie RI, Kreeft J, Bridger E (1976) Correlation of disopyramide pharmacokinetics with efficacy in ventricular tachyarrhythmia. J Int Med Res [Suppl I] 4:54–58Google Scholar
  208. Rees A, Dalai JJ, Reid PG, Henderson AH, Lewis MJ (1981) Dangers of amiodarone and anticoagulant treatment. Br Med J 282:1756–1757Google Scholar
  209. Regårdh C-G, Johnsson G, Lundborg P, Persson B-A (1977) Bioavailability of quinidine in slow-release form. Arzneim-Forsch/Drug Res 27:1716–1718Google Scholar
  210. Reidenberg MM, Odar-Cederlöf I, von Bahr C, Borgå O, Sjöqvist F (1971) Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med 285:264–267PubMedGoogle Scholar
  211. Reidenberg MM, Drayer DE, Levy M, Warner H (1975) Polymorphic acetylation of procainamide in man. Clin Pharmacol Ther 17:722–730PubMedGoogle Scholar
  212. Reynolds EH (1978) Drug treatment of epilepsy. Lancet 2:721–725PubMedGoogle Scholar
  213. Rodin EA, De Sousa G, Haidukewych D, Lodhi R, Berchou RC (1981) Dissociation between free and bound phenytoin levels in presence of valproate sodium. Arch Neurol 38:240–242PubMedGoogle Scholar
  214. Roe TF, Podosin RL, Blaskovics ME (1975) Drug interaction: Diazoxide and diphenylhydantoin. J Pediatr 9:285Google Scholar
  215. Ronfeld RA (1980) Comparative pharmacokinetics of new antiarrhythmic drugs. Am Heart J 100:978–983PubMedGoogle Scholar
  216. Ronfeld RA, Wolshin EM, Block AJ (1980) Tocainide and metabolites: Human pharmacokinetics and animal pharmacology. Clin Pharmacol Ther 27:282Google Scholar
  217. Rosenbaum MB, Chiale PA, Nau GJ, Przybylski J, Levi RJ, Lazzari JO, Elizari MV (1976) Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol 38:934–944PubMedGoogle Scholar
  218. Routledge PA, Barchowsky A, Bjornssen TD, Kitchell BB, Shand DG (1980a) Lidocaine plasma protein binding. Clin Pharmacol Ther 27:347–351PubMedGoogle Scholar
  219. Routledge PA, Stargel WW, Wagner GS, Shand DG (1980b) Increased alpha-1-acid glycoprotein and lidocaine disposition in myocardial infarction. Ann Intern Med 93:701–704PubMedGoogle Scholar
  220. Routledge PA, Shand DG, Barchowsky A, Wagner G, Stargel WW (1981) Relationship between α 1-acid glycoprotein and lidocaine disposition in myocardial infarction. Clin Pharmacol Ther 30:154–157PubMedGoogle Scholar
  221. Rowland M, Thomson PD, Guichard A, Melmon KL (1971) Disposition kinetics of lidocaine in normal subjects. Ann NY Acad Sci 179:383–398PubMedGoogle Scholar
  222. Rowland M, Tozer TN (1980) Clinical pharmacokinetics: Concepts and applications. Lea & Febiger, Philadelphia, USAGoogle Scholar
  223. Saetre H, Ahlmark G, Ahlberg G (1974) Haemodynamic effects of ajmaline in man. Eur J Clin Pharmacol 7:253–257PubMedGoogle Scholar
  224. Schaumlöffel E (1974) Pharmakokinetische Studien mit radioaktiv markiertem N-Propylajmalinium-hydrogentartrat an Ratte und Mensch. Med Welt 25:2008–2014PubMedGoogle Scholar
  225. Schomerus M, Spiegelhaider B, Stieren B, Eichelbaum M (1976) Physiological disposition of verapamil in man. Cardiovasc Res 10:605–612PubMedGoogle Scholar
  226. Schwartz ML, Meyer MB, Covino BG, Narang RM, Sethi V, Schwartz AJ, Kamp P (1974) Antiarrhythmic effectiveness of intramuscular lidocaine: Influence of different injection sites. J Clin Pharmacol 14:77–83PubMedGoogle Scholar
  227. Shand DG, Hammill SC, Aanonsen L, Pritchell ELC (1981) Reduced verapamil clearance during long-term oral administration. Clin Pharmacol Ther 30:701–703PubMedGoogle Scholar
  228. Simons KJ, Levy RH, Cutler RE, Christopher GT, Lindner A (1975) The pharmacokinetics of procainamide in normal subjects using a specific gas chromatographic assay. Res Commun Chem Pathol Pharmacol 11:173–185PubMedGoogle Scholar
  229. Singh BN, Cho YW, Kuemmerle HP (1981) Clinical pharmacology of antiarrhythmic drugs: a review and overview. Int J Clin Pharmacol Ther Toxicol 19:139–151, 185–199Google Scholar
  230. Smith ER, Duce BR (1971) The acute antiarrhythmic and toxic effects in mice and dogs of 2-ethylamino-2′6′-acetoxylidine (1–86) a metabolite of lidocaine in man. J Pharmacol Exp Ther 179:580–585PubMedGoogle Scholar
  231. Soda DM, Levy G (1975) Inhibition of drug metabolism by hydroxylated metabolites: Cross-inhibition and specificity. J Pharm Sci 64:1928–1931PubMedGoogle Scholar
  232. Somani P (1981) Pharmacokinetics of lorcainide, a new antiarrhythmic drug, in patients with cardiac rhythm disorders. Am J Cardiol 48:157–163PubMedGoogle Scholar
  233. Somogyi A, Albrecht M, Kliems K, Schäfer K, Eichelbaum M (1981) Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. Br J Clin Pharmacol 12:51–60PubMedGoogle Scholar
  234. Stäubli M, Studer H (1981) Behandlung der Arrhythmien mit Amiodaron. Schweiz Med Wochenschr 111:460–465PubMedGoogle Scholar
  235. Stäubli M, Bischof P, Wimpfheimer C, Studer H (1981) Amiodaron (Cordarone) und Schilddrüse. Schweiz Med Wochenschr 111:1590–1596PubMedGoogle Scholar
  236. Stenson RE, Constantino RT, Harrison DC (1971) Interrelationships of hepatic blood flow, cardiac output, and blood levels of lidocaine in man. Circulation 43:205–211PubMedGoogle Scholar
  237. Stern S (1967) Conversion of chronic atrial fibrillation to sinus rhythm with combined propranolol and quinidine treatment. Am Heart J 74:170–172PubMedGoogle Scholar
  238. Strong JM, Dutcher JS, Lee WK, Atkinson AJ (1975) Pharmacokinetics in man of the N-acetylated metabolite of procainamide. J Pharm Biopharm 3:223–235Google Scholar
  239. Talbot RG, Clark RA, Nimmo J, Neilson JMM, Julian DG, Prescott LF (1973) Treatment of ventricular arrhythmias with mexiletine (Kö 1173). Lancet 2:399–404PubMedGoogle Scholar
  240. Thomson PD, Melmon KL, Richardson JA, Cohn K, Steinbrunn W, Cudihee R, Rowland M (1973) Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med 78:499–508PubMedGoogle Scholar
  241. Tjandramaga TB, Verbesselt R, De Schepper PJ (1981) Disposition of intravenous lorcainide in patients on maintenance oral therapy with β-adrenoceptor blocking agents. In: Jähnchen E, Meinertz T, Towse G (eds) Prognosis and pharmacotherapy of life-threatening arrhythmias. Royal Society of Medicine. Int Congress and Symposium Series No 49. Academic Press, London, pp 51–55Google Scholar
  242. Tucker GT, Boas RA (1971) Pharmacokinetic aspects of intravenous regional anaesthesia. Anaesthesiology 34:538–550Google Scholar
  243. Ueda CT, Dzindzio BS (1978) Quinidine kinetics in congestive heart failure. Clin Pharmacol Ther 23:158–164PubMedGoogle Scholar
  244. Ueda CT, Hirschfeld DS, Scheinman MM, Rowland M, Williamson BJ, Dzindzio BS (1976) Disposition kinetics of quinidine. Clin Pharmacol Ther 19:30–36PubMedGoogle Scholar
  245. Valentine PA, Frew JL, Mashford ML, Sloman JG (1974) Lidocaine in the prevention of sudden death in the prehospital phase of acute infarction. A double-blind study. N Engl J Med 291:1327–1331PubMedGoogle Scholar
  246. Van Durme JP, Bogaert MG, Rousseel M-T (1974) Therapeutic effectiveness and plasma levels of aprindine, a new antidysrhythmic drug. Eur J Clin Pharmacol 7:343–346PubMedGoogle Scholar
  247. Ward JW, Kinghorn GR (1976) The pharmacokinetics of disopyramide following myocardial infarction with special reference to oral and intravenous dose regimens. J Int Med Res [Suppl I] 4:49–53Google Scholar
  248. Wesseling H, Mols-Thürkow I (1975) Interaction of diphenylhydantoin (DPH) and tolbutamide in man. Eur J Clin Pharmacol 8:75–78PubMedGoogle Scholar
  249. Whiting B, Elliott HL (1977) Disopyramide in renal impairment. Lancet 2:1363PubMedGoogle Scholar
  250. Wiebringhaus E, Seipel L, Breithardt G, Loogen F (1977) Langzeitergebnisse mit dem neuen Antiarrhythmikum Propafenon unter Berücksichtigung der Plasmaspiegel. Z Kardiol 66:625–632PubMedGoogle Scholar
  251. Wiegand U-W, Nitsche T, Just H, Bechtold H, Meinertz T (1982) The pharmacokinetics of lorcainide in patients with liver disease. Naunyn Schmiedebergs Arch Pharmacol [Suppl] 319:R 83Google Scholar
  252. Wiegers U, Kuck KH, Hanrath P, Pottage A, Augustin J, Bleifeld W (1980) Pharmakokinetik von Tocainide bei Patienten mit Niereninsuffizienz. Z Kardiol 10:717Google Scholar
  253. Wilson JT, Hojer B, Tomson G, Rane A, Sjöqvist F (1978) High incidence of a concentration dependent skin reaction in children treated with phenytoin. Br Med J 1:1583–1586PubMedGoogle Scholar
  254. Wing LMH, Meffin PJ, Grygiel JJ, Smith KJ, Birkett DJ (1980) The effect of metoclopramide and atropine on the absorption of orally administered mexiletine. Br J Clin Pharmacol 9:505–509PubMedGoogle Scholar
  255. Winkle RA, Meffin PJ, Fitzgerald JW, Harrison DC (1976) Clinical efficacy and pharmacokinetics of a new orally effective antiarrhythmic, tocainide. Circulation 54:884–889Google Scholar
  256. Woo E, Greenblatt DJ (1978) Reevaluation of intravenous quinidine. Am Heart J 96:829–832PubMedGoogle Scholar
  257. Woo E, Greenblatt DJ (1979) Pharmacokinetic and clinical implications of quinidine protein binding. J Pharm Sci 68:466–470PubMedGoogle Scholar
  258. Woodcock BG, Hopf R, Kaltenbach M (1980) Verapamil and Norverapamil plasma concentrations during long-term therapy in patients with hypertrophic obstructive cardiomyopathy. J Cardiovasc Pharmacol 2:17–23PubMedGoogle Scholar
  259. Woodcock BG, Rietbrock I, Vöhringer HF, Rietbrock N (1981) Verapamil disposition in liver disease and intensive-care patients: Kinetics, clearance, and apparent blood flow relationships. Clin Pharmacol Ther 29:27–34PubMedGoogle Scholar
  260. Woosley RL, Shand DG (1978) Pharmacokinetics of antiarrhythmic drugs. Am J Cardiol 41:986–995PubMedGoogle Scholar
  261. Woosley RL, McDevitt DG, Nies AS, Smith RF, Wilkinson GR, Oates JA (1977) Suppression of ventricular ectopic depolarizations by tocainide. Circulation 56:980–984PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1983

Authors and Affiliations

  • E. Jähnchen
  • D. Trenk

There are no affiliations available

Personalised recommendations